- Record: found
- Abstract: found
- Article: not found
Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Robert A Burger
1 ,
Mark F Brady ,
Michael A Bookman ,
Gini F Fleming ,
Bradley J Monk ,
Helen Huang ,
Robert S Mannel ,
Howard D Homesley ,
Jeffrey Fowler ,
Benjamin E Greer ,
Matthew Boente ,
Michael J Birrer ,
Sharon X Liang
Dec 29 2011
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Vascular endothelial growth factor is a key promoter of angiogenesis and disease progression in epithelial ovarian cancer. Bevacizumab, a humanized anti-vascular endothelial growth factor monoclonal antibody, has shown single-agent activity in women with recurrent tumors. Thus, we aimed to evaluate the addition of bevacizumab to standard front-line therapy.